{"url_path":"/sec/ptct/8-k/2026-06-16/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/1070081/0001104659-26-074292-index.html","accession_number":"0001104659-26-074292","cik":"0001070081","ticker":"PTCT","issuer_name":"PTC THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1070081/0001104659-26-074292-index.html","primary_entity_key":"0001070081","primary_entity_name":"PTC THERAPEUTICS, INC."},"word_count":372,"has_tables":true,"body_markdown":"**Item 8.01.\nOther Events.**\n\n \n\nOn June 15, 2026, PTC Therapeutics, Inc. (the “Company”)\nissued a press release announcing the pricing of its previously announced offering (the “Offering”) of $500.0 million aggregate\nprincipal amount of 0.00% Convertible Senior Notes due 2031 (the “Notes”). The Company also granted the initial purchasers\nan option to purchase, within the 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional\n$50.0 million aggregate principal amount of Notes. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated\nherein by reference.\n\n \n\nThe Company expects to use approximately $328.8 million of the net\nproceeds from the Offering to repurchase for cash $222.0 million in aggregate principal amount of the Company’s outstanding 1.5%\nConvertible Senior Notes due 2026 (the “2026 Notes”) pursuant to privately negotiated transactions with certain holders entered\ninto concurrently with the pricing of the Notes. The remaining net proceeds from the Offering will be used for general corporate purposes,\nwhich may include additional repurchases of the 2026 Notes from time to time following the Offering and the repayment or retirement of\nany remaining 2026 Notes at maturity. This report is not a notice of redemption or an offer to repurchase the 2026 Notes, and the Offering\nof the Notes is not contingent upon the repurchase of any of the 2026 Notes.\n\n \n\nThe offer and sale of the Notes and any shares of Common Stock issuable\nupon conversion of the Notes have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities\nAct”) or any other securities laws, and the Notes and any such shares cannot be offered or sold except pursuant to an exemption\nfrom, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.\n\n \n\nThis report does not constitute an offer to sell, or the solicitation\nof an offer to buy, the Notes or any shares of the Common Stock issuable upon conversion of the Notes, nor will there be any sale of\nthe Notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful."}